Specific approval indications include treatment of early HER2+ breast cancer with residual disease after neoadjuvant treatment with trastuzumab and taxane therapy [11] and metastatic HER2+ breast cancer previously treated with trastuzumab and a taxane [12,13]. Here, ERBB2 is linked to breast cancer.